FPI-2265 is a small molecule commercialized by Fusion Pharmaceuticals, with a leading Phase II program in Metastatic Castration-Resistant Prostate Cancer (mCRPC). According to Globaldata, it is involved in 3 clinical trials, of which 1 is ongoing, and 2 are planned. GlobalData uses proprietary data and analytics to provide a complete picture of FPI-2265’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
The revenue for FPI-2265 is expected to reach an annual total of $24 mn by 2035 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
FPI-2265 is under development for the treatment of metastatic hormone refractory (castration resistant, androgen-independent) prostate cancer. It is administered through intravenous route. The therapeutic candidate comprises a radionuclide targeting cells expressing prostate specific membrane antigen (PSMA).
Fusion Pharmaceuticals Overview
Fusion Pharmaceuticals is a clinical-stage biopharmaceutical company which develops targeted alpha-particle radio therapeutics for the treatment of cancers. It offers pipeline products such as FPI-1434, FPI-2059 and FPI-1966. The company’s pipeline products treat multiple cancers like head and neck bladder cancer, colorectal cancer and gastric cancers. It aslo include mono therapy and combination therapy. Fusion Pharmaceuticals carters its products under brand Keytruda. It has its operations in the US and Canada. Fusion Pharmaceuticals is headquartered in Hamilton, Ontario, Canada.
The company reported revenues of (US Dollars) US$1.5 million for the fiscal year ended December 2022 (FY2022), an increase of 1.5% over FY2021. The operating loss of the company was US$88 million in FY2022, compared to an operating loss of US$82 million in FY2021. The net loss of the company was US$87.6 million in FY2022, compared to a net loss of US$81.1 million in FY2021.
For a complete picture of FPI-2265’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.